Nad+ supplement

Most supplement companies sell what they call NAD+ precursors — not actual NAD+. The molecule is too large and unstable to survive oral administration intact. What you're actually getting, in nearly every commercial product, is nicotinamide riboside (NR) or nicotinamide mononucleotide (NMN), compounds that cells can convert into NAD+ through salvage pathways. Whether this conversion happens efficiently enough to matter is the question the research has only partially answered.

NAD+ Is a Coenzyme, Not a Single Molecule You Take

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme present in every living cell. It exists in two forms: NAD+ (oxidized) and NADH (reduced). These forms shuttle electrons in redox reactions — the fundamental chemistry of energy metabolism. NAD+ accepts electrons during glycolysis and the citric acid cycle; NADH donates them in the electron transport chain to generate ATP.

Beyond energy metabolism, NAD+ serves as a substrate for three enzyme families: sirtuins (protein deacetylases), PARPs (DNA repair enzymes), and CD38/CD157 (glycohydrolases involved in calcium signaling). These enzymes cleave the nicotinamide-glycosidic bond in NAD+, consuming it in the process. This consumption is why NAD+ levels matter — chronic activation of sirtuins or PARPs under metabolic or genotoxic stress depletes cellular NAD+, potentially limiting the capacity for further enzymatic activity.

NAD+ levels decline with age in multiple tissues. In mice, hepatic NAD+ drops by approximately 50% between 3 and 27 months of age. Human skin fibroblasts show similar declines in culture. The mechanisms include increased consumption (CD38 expression rises with age in several tissues) and decreased synthesis from tryptophan via the de novo pathway. Whether this decline is causative or correlative with aging phenotypes remains an open question.

The molecule itself — a dinucleotide with a molecular weight of 663 Da — does not cross cell membranes intact in most tissues. Oral NAD+ is hydrolyzed in the gut. IV NAD+ is rapidly degraded in plasma by ectonucleotidases. What enters cells are the breakdown products or smaller precursors: nicotinamide (NAM), nicotinamide riboside (NR), or nicotinamide mononucleotide (NMN). These feed into salvage pathways that synthesize NAD+ intracellularly.

The Salvage Pathway Is How Cells Rebuild NAD+ from Precursors

Mammalian cells synthesize NAD+ through three routes: the de novo pathway (from tryptophan), the Preiss-Handler pathway (from nicotinic acid), and the salvage pathway (from nicotinamide, NR, or NMN). The salvage pathway dominates in most tissues because dietary NAD+ breakdown products are abundant and the pathway is energetically efficient.

Nicotinamide — the breakdown product of NAD+-consuming reactions — is converted to NMN by nicotinamide phosphoribosyltransferase (NAMPT), the rate-limiting enzyme. NMN is then converted to NAD+ by NMN adenylyltransferases (NMNATs), which exist in the nucleus (NMNAT1), Golgi (NMNAT2), and mitochondria (NMNAT3). This compartmentalization suggests NAD+ pools are semi-independent within organelles.

NR, a precursor found in trace amounts in milk, is phosphorylated to NMN by nicotinamide riboside kinases (NRK1 and NRK2). NR bypasses NAMPT, which is why it was initially proposed as a superior NAD+ booster — NAMPT expression declines with age and is feedback-inhibited by nicotinamide. In practice, NR supplementation does raise NAD+ levels in rodent tissues, but the magnitude depends on tissue type, dose, and baseline NAD+ status.

NMN is one enzymatic step closer to NAD+ than NR, which led to speculation that it would be more effective. However, NMN is not a known substrate for any mammalian membrane transporter in most tissues — a 2019 study in Nature Metabolism found that oral NMN is dephosphorylated to NR in the gut before absorption, then re-phosphorylated intracellularly. This means NMN and NR may be functionally equivalent after oral administration. For research purposes only, intraperitoneal NMN in mice bypasses gut metabolism and does appear to enter some tissues directly, though the transporter identity remains debated.

Rodent Studies Show NAD+ Precursors Improve Metabolic and Cognitive Outcomes in Aging and Disease Models

NR supplementation (400 mg/kg/day, oral) in aged mice increased hepatic NAD+ by approximately 60% and improved mitochondrial function, as measured by oxygen consumption and citrate synthase activity. A separate study in high-fat-diet-induced obese mice found that NR (400 mg/kg/day) reduced weight gain, improved glucose tolerance, and increased energy expenditure, effects attributed to activation of SIRT1 and mitochondrial biogenesis pathways via PGC-1α.

In the APP/PS1 mouse model of Alzheimer's disease, NR (250 mg/kg/day for 3 months) reduced amyloid plaque burden in the cortex and hippocampus, improved cognitive performance in the Morris water maze, and reduced neuroinflammation markers. The mechanism appeared to involve SIRT3-mediated mitochondrial protection and reduced oxidative stress. These results were published in PNAS in 2016 and have been partially replicated in other neurodegeneration models.

NMN produced similar effects in several rodent aging studies. In 22-month-old C57BL/6 mice, NMN (300 mg/kg/day, oral, for 12 months) improved insulin sensitivity, increased physical activity, and enhanced mitochondrial oxidative metabolism in skeletal muscle. The same dose in a mdx mouse model of muscular dystrophy improved muscle pathology and increased running endurance. The NAD+-dependent deacetylase SIRT1 was required for many of these effects — genetic deletion of SIRT1 abolished the metabolic benefits of NMN in some tissues.

A 2021 study in Cell Metabolism found that NMN supplementation restored capillary density in aged mice, improved blood flow in hindlimb ischemia, and increased exercise capacity. The mechanism involved activation of SIRT1 in endothelial cells, leading to increased nitric oxide production and angiogenesis. This aligns with earlier findings that NAD+ depletion impairs endothelial function and that sirtuin activity is critical for vascular health.

Human data is thinner. A 2018 randomized, double-blind trial in 120 healthy adults (NR 250-1000 mg/day for 8 weeks) showed dose-dependent increases in blood NAD+ levels — up to 2.7-fold at 1000 mg/day — but no significant changes in metabolic outcomes (insulin sensitivity, blood pressure, lipid profile). A smaller 2022 trial in 25 postmenopausal women with prediabetes (NR 1000 mg/day for 10 weeks) found improved insulin sensitivity in muscle but no effect on hepatic glucose production. A 2021 MIB-626 (a microcrystalline NMN formulation) study in 32 overweight adults found improved muscle insulin sensitivity and aerobic capacity after 250 mg twice daily for 10 days, but the sample size was small and the trial was unblinded.

Dosing, Bioavailability, and Stability in Published Research

Rodent studies typically use 250-500 mg/kg/day NR or NMN, administered orally in drinking water or by gavage. Scaled to human equivalent doses using body surface area (a common but imperfect conversion), this translates to roughly 20-40 mg/kg in humans, or 1400-2800 mg/day for a 70 kg adult. Most human trials have used 250-1000 mg/day NR or 250-500 mg NMN, which is substantially lower than the rodent-equivalent doses.

Oral bioavailability of NR in humans has not been precisely determined. A 2016 pharmacokinetic study found that oral NR (1000 mg single dose) increased whole blood NAD+ by 2.7-fold at 8 hours, suggesting systemic absorption and tissue distribution. However, blood NAD+ levels do not necessarily reflect intracellular NAD+ in metabolically active tissues like muscle, liver, or brain.

NMN bioavailability is similarly unclear. The 2019 finding that NMN is dephosphorylated to NR in the gut suggests that much of oral NMN is absorbed as NR. Some researchers argue this makes NMN supplementation redundant, though direct comparisons in humans are lacking. One pharmacokinetic study in Japanese men (100-500 mg oral NMN) detected a transient rise in plasma NMN at 15 minutes, but levels returned to baseline by 120 minutes, and no increase in blood NAD+ was reported.

Stability is a practical issue. NR is hygroscopic and degrades in the presence of moisture, heat, or light. Commercial formulations use chloride or iodide salts to improve stability. NMN is similarly labile — studies have found significant degradation in capsules stored at room temperature over weeks. Refrigeration slows but does not eliminate degradation. Sublingual or liposomal formulations have been marketed with claims of improved bioavailability, but no peer-reviewed data supports these claims for NAD+ precursors.

NAD+ itself has a short half-life in circulation — minutes, not hours. Tissue NAD+ half-life is longer (hours to days depending on the tissue and metabolic state), but systemic administration of NAD+ (by IV infusion, as used in some wellness clinics) is unlikely to produce sustained intracellular elevation. The rapid degradation by CD38 and other ectonucleotidases in plasma means that free NAD+ does not persist long enough to enter most tissues in meaningful amounts.

FAQ

Q: Is NMN better than NR for raising NAD+ levels?

In rodent studies, both NMN and NR increase tissue NAD+ levels at similar doses. The 2019 evidence that oral NMN is converted to NR in the gut suggests they may be functionally equivalent after oral administration. Some tissues may preferentially use one precursor over the other, but head-to-head human trials comparing NMN and NR at equivalent doses do not exist. The claim that NMN is "one step closer" to NAD+ may not be relevant if it must be dephosphorylated and re-phosphorylated after absorption.

Q: Do NAD+ precursors actually extend lifespan?

In short-lived organisms (yeast, worms, flies), NAD+ precursors or sirtuin activators have extended lifespan in some studies, though results are inconsistent and appear strain- and diet-dependent. In mice, chronic NR or NMN supplementation has not been shown to extend maximum lifespan in well-controlled longevity studies. The metabolic and healthspan improvements observed in aged mice do not always translate to lifespan extension — a common pattern in aging research. Human lifespan data does not exist.

Q: Can I get enough NAD+ precursors from food?

NR is present in trace amounts in milk (nanomolar concentrations). Nicotinamide is more abundant in meat, fish, and fortified grains. The average Western diet provides roughly 20-40 mg/day of nicotinamide equivalents. This is sufficient to prevent pellagra (niacin deficiency) but may not optimize tissue NAD+ levels, especially in aging or metabolic disease states where NAD+ consumption is elevated. Whether dietary intake can match the tissue NAD+ increases seen with high-dose precursor supplementation is unlikely based on dose-response data.

Q: What are the side effects of high-dose NAD+ precursors?

NR at doses up to 1000 mg/day and NMN at doses up to 500 mg/day have been well-tolerated in short-term human trials (8-12 weeks). Mild gastrointestinal discomfort and flushing have been reported at higher doses, likely due to nicotinamide accumulation. One concern is that chronic high-dose nicotinamide inhibits sirtuins (negative feedback), potentially blunting the benefits of NAD+ elevation. Long-term safety data beyond 6 months does not exist. Methylation demand increases with nicotinamide metabolism, which could theoretically deplete methyl donors in individuals with low folate or B12 status, though this has not been documented clinically.

Q: Does NAD+ supplementation help with fatigue or brain fog?

Anecdotal reports of improved energy and mental clarity are common in online forums, but placebo-controlled trials have not consistently demonstrated subjective benefits. The 2018 NR trial found no significant change in self-reported energy or cognitive function. The metabolic improvements (insulin sensitivity, mitochondrial function) seen in some trials may take weeks to manifest and may not produce noticeable subjective effects. One small trial in chronic fatigue syndrome patients (NR 1000 mg/day) is ongoing but results have not been published.

The research on NAD+ precursors is extensive in rodents, suggestive in humans, and far from conclusive. The biological rationale is sound — NAD+ is required for fundamental cellular processes and declines with age — but whether supplementation produces clinically meaningful outcomes in healthy humans remains an open question. This information is provided for educational purposes and is not intended to diagnose, treat, cure, or prevent any disease. Consult a qualified healthcare provider before using any research compound.